## Katherine Tsaioun

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6404465/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	GRADE Guidelines 30: the GRADE approach to assessing the certaintyÂof modeled evidence—An overview in the context of healthÂdecision-making. Journal of Clinical Epidemiology, 2021, 129, 138-150.	2.4	81
2	Evidence-based absorption, distribution, metabolism, excretion (ADME) and its interplay with alternative toxicity methods. ALTEX: Alternatives To Animal Experimentation, 2016, 33, 343-358.	0.9	75
3	A primer on systematic reviews in toxicology. Archives of Toxicology, 2017, 91, 2551-2575.	1.9	68
4	ADDME – Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective. BMC Neurology, 2009, 9, S1.	0.8	65
5	Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 647-660.	1.5	46
6	Toward good in vitro reporting standards. ALTEX: Alternatives To Animal Experimentation, 2019, 36, 3-17.	0.9	46
7	QSAR-based permeability model for drug-like compounds. Bioorganic and Medicinal Chemistry, 2011, 19, 2615-2624.	1.4	41
8	Software tools for literature screening in systematic reviews in biomedical research. ALTEX: Alternatives To Animal Experimentation, 2019, 36, 508-517.	0.9	39
9	Quantitative Systems Pharmacology for Neuroscience Drug Discovery and Development: Current Status, Opportunities, and Challenges. CPT: Pharmacometrics and Systems Pharmacology, 2020, 9, 5-20.	1.3	29
10	Probabilistic risk assessment $\hat{a} \in $ the keystone for the future of toxicology. ALTEX: Alternatives To Animal Experimentation, 2022, 39, 3-29.	0.9	28
11	Performance of preclinical models in predicting drug-induced liver injury in humans: a systematic review. Scientific Reports, 2021, 11, 6403.	1.6	27
12	De-Risking Drug Discovery with ADDME — Avoiding Drug Development Mistakes Early. ATLA Alternatives To Laboratory Animals, 2009, 37, 47-55.	0.7	14
13	Reviewing the animal literature: how to describe and choose between different types of literature reviews. Laboratory Animals, 2021, 55, 129-141.	0.5	14
14	Better science for safer medicines: the human imperative. Journal of the Royal Society of Medicine, 2018, 111, 433-438.	1.1	12
15	The effect of radiofrequency electromagnetic fields (RF-EMF) on biomarkers of oxidative stress in vivo and in vitro: A protocol for a systematic review. Environment International, 2022, 158, 106932.	4.8	10
16	Adaptation of the Systematic Review Framework to the Assessment of Toxicological Test Methods: Challenges and Lessons Learned With the Zebrafish Embryotoxicity Test. Toxicological Sciences, 2019, 171, 56-68.	1.4	9
17	COVID-19 through Adverse Outcome Pathways: Building networks to better understand the disease – 3rd CIAO AOP Design Workshop. ALTEX: Alternatives To Animal Experimentation, 2022, , .	0.9	9
18	A Systematic Review to Compare Chemical Hazard Predictions of the Zebrafish Embryotoxicity Test With Mammalian Prenatal Developmental Toxicity. Toxicological Sciences, 2021, 183, 14-35.	1.4	7

KATHERINE TSAIOUN

#	Article	IF	CITATIONS
19	Applying evidence-based methods to the development and use of adverse outcome pathways. ALTEX: Alternatives To Animal Experimentation, 2021, 38, 336-347.	0.9	7
20	Biological plausibility in environmental health systematic reviews: a GRADE concept paper. Environment International, 2022, 162, 107109.	4.8	7
21	Biological plausibility in environmental health systematic reviews: aÂGRADE concept paper. Journal of Clinical Epidemiology, 2022, 146, 32-46.	2.4	5
22	Optimizing the use of CROs by academia and small companies. Nature Reviews Drug Discovery, 2013, 12, 487-488.	21.5	4
23	Systematic review in evidence-based risk assessment. ALTEX: Alternatives To Animal Experimentation, 2021, , .	0.9	3
24	Safety of medicine and the use of animals in research. Lancet, The, 2011, 378, e2.	6.3	2
25	ADME (Absorption, Distribution, Metabolism, Excretion): The Real Meaning—Avoiding Disaster and Maintaining Efficacy for Preclinical Candidates. , 2012, , 617-638.		1
26	VC Firms Must Change Early-Stage Investment Strategies. Genetic Engineering and Biotechnology News, 2011, 31, 6-8.	0.1	0
27	Chapter 6. Human in Vitro ADMET and Prediction of Human Pharmacokinetics and Toxicity Liabilities at the Discovery Stage. RSC Drug Discovery Series, 2014, , 110-131.	0.2	0
28	De-Risking Drug Discovery Programmes Early with ADMET. , 0, , .		0
29	EFSA – Johns Hopkins Food Safety Symposium 2019. ALTEX: Alternatives To Animal Experimentation, 2020, 37, 312-314.	0.9	0
30	Kinase signaling as a drug target modality for regulation of vascular hyperpermeability: A case for ARDS therapy development. Drug Discovery Today, 2022, , .	3.2	0